I am still very on the fence on this since the Adcom. I hope we all make money when the decision arrives
MarkyBoy212
praėjusią savaitę
A new buy rating and 2 maintained buys very nice
A new buy rating and 2 maintained buys very nice, hoping this gets approval after earnings and award
ByronKS
praėjusią savaitę
Capricor earnings report
See the Capricor Therapeutics earnings report below. Good luck! 🤞🏼🍀
https://web.quartr.com/link/companies/5913/events/732825/report?rp=0&documentId=4012432
MarkyBoy212
prieš 2 savaites
Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology
Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology
TerraNova23
prieš 2 savaites
Anyone else think this will fail?
According to Adam Feuerstein, Capricor faces two major risks:
Weak Clinical Evidence: The FDA may consider Deramiocel's efficacy data insufficient for approval.
Public Pressure on the FDA: Capricor's public statements could suggest concerns about its chances of approval.
And there is still the 3-9 vote from before.
Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress
Prayers
prieš 3 mėnesius
This too (and yh I DO wish I did this in CFD lol)
GGGGM
prieš 3 mėnesius
Thank God for this stock today
$CAPR to the rescue, thank you thus far... NFA
kosen
prieš 3 mėnesius
This pattern looks exactly like yesterday.
If it completely duplicates yesterday’s pattern, we see 11.5 Today???
kosen
prieš 3 mėnesius
What do we think
At a loss now, watching a bit
GGGGM
prieš 3 mėnesius
We going up.. The News is here.. NFA.
$CAPR would soar today as the long awaited news is finally here.
The FDA accepted a major amendment to Capricor's Biologics License Application (BLA) containing 24-month Phase 3 HOPE-3 extension data. Instead of issuing an immediate rejection, the FDA extended the PDUFA target action date to November 22, 2026.
I got in early at $8 and waiting to see above 11 and above..
Note that THIS IS NOT A FINANCIAL ADVICE... NFA
SKM2086
prieš 3 mėnesius
PT - $54
I'm going with a conservative $25-30. We're on the right track now. Definitely close to making permanent moves upwards.
https://uk.investing.com/news/stock-market-news/oppenheimer-upgrades-capricor-stock-rating-on-regulatory-update-93CH-4846076
MarkyBoy212
prieš 3 mėnesius
Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA
Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA nice news guys
Hazlaw1234
prieš 3 mėnesius
$CAPR feels like one to watch very closely today 👀
The official PDUFA target date is tomorrow, Saturday 22 August, but with that falling on a weekend there’s a very real possibility we hear something from the FDA today instead.
As of now there’s been no decision announced, so I’d expect a lot of eyes on CAPR once the US session gets going and especially into after hours.
Could be a very important day for the stock. Definitely worth keeping notifications on.
NFA
Šiame puslapyje gali būti bendruomenės sukurto turinio, už kurį „Trading 212“ neatsako. Visada atlik savo tyrimą. „Trading 212“ teikia tik vykdymo paslaugą, bet neteikia investavimo konsultacijų ar portfelio valdymo paslaugų.
Turto kaupimas – įprotis. Automatizuokite jį naudodami Pies.
Investuok į paruoštus arba susikurk savo investicijų rinkinius, pasirinkdamas iš daugybės vertybinių popierių ir ETF
Sužinok daugiau
Sužinok daugiau
Žiūrėti vaizdo įrašą
Turėk net brangiausių akcijų, tokių kaip „Google“, „Amazon“ ir „Apple“
Žiūrėti vaizdo įrašą
„Euronext“ Paryžius
NYSE, NASDAQ
Xetra, Gettex
Euronext Amsterdam
Bolsa de Madrid
Wiener Börse
Londono vertybinių popierių birža
„Euronext Lisbon“
„Euronext“ Paryžius
NYSE, NASDAQ
Xetra, Gettex
Euronext Amsterdam
Bolsa de Madrid
Wiener Börse
Londono vertybinių popierių birža
„Euronext Lisbon“
Peržiūrėk visas prekybos priemones
Pagalba visą parą
29 sekundžių vidutinis atsako laikas
Pradėk kaupti turtą jau dabar
Prisijunk prie daugiau nei 5 mln. naudotojų
Atsisiųsti programėlę
Atidaryti sąskaitą
Atsisiųsk mobiliąją programėlę
Visi pateikti statistiniai duomenys yra globalūs. Klientų skaičius atspindi finansuotas sąskaitas.
Puiku
Įvertinta 4,6/5, remiantis 108 764 atsiliepimais apie
Trustpilot
Įvertinta 4,6/5, remiantis 108 764 atsiliepimais apie
Trustpilot
Pakviestas
Great app very easy to use and lots of…
Great app very easy to use and lots of information. Always upto date with balances and share prices etc.
Pakviestas
Smooth experience
The whole thing is smooth and seamless and makes things easy overall.
Pakviestas
Really easy to use
Really easy to use. Secure and has the best functionality and features.
Pakviestas
Easy to keep up with as informed…
Easy to keep up with as informed everyday or week on interest made . Easy to set up account . No problems .
Pakviestas
Easy to operate and work with
Easy to operate and work with. Works very fast and accurately.
Pakviestas
How you rate the app
This app is so easy to use and safe really love it.
Pakviestas
I opened a cash ISA with them
I opened a cash ISA with them. It was really straightforward to do and interest is added daily. Nice ,easy to use app as well.
Pakviestas
Easy to navigate makes investing…
Easy to navigate makes investing interesting, transferred my investments from HL which was very straightforward and now not paying dealing fee’s
Very Happy
Pakviestas
App is easy to work
App is easy to work
Good interest rate
Daily interest updates
Pakviestas
Very good and informative always stay…
Very good and informative always stay on track with your investments
Pakviestas
Reliable
Reliable, trustworthy app to store your money and to build on your existing wealth if you are financially sensible and smart.
Pakviestas
Great app
Great app. I would recommend to anyone that’s into investing and making their money grow .
Pakviestas
Very easy app to register and use
Very easy app to register and use! Really pleased.
Pakviestas
Clear app
Clear app. Easy to invest. Took a whike for money to get in because i did it from bank rather than in app
Pakviestas
Very smooth and user friendly
Very smooth and user friendly. Have had zero issues having moved from other brokerages. Will keep using.
Pakviestas
Easy to set up and to regular monitor…
Easy to set up and to regular monitor how its performing.
Pakviestas
Competitive rates and quick transfers
Very good on money transfers in and out. They take place immediately unlike some other providers.
Very competitive rate on Cash ISA
Pakviestas
Customer support is quick and…
Customer support is quick and effective. The app is well organised and easy to use. Would reccommend for anyone even complete beginners.
Pakviestas
Easy to set up the Cash ISA
Easy to set up the Cash ISA, funds arrived in account almost immediately. Great to see interest accrual amounts daily.
Pakviestas
Reliable
Reliable, Secure. Using it for past 3 years
Pateikiami keli teigiami mūsų klientų atsiliepimai
Mūsų apdovanojimai
Dažniausiai užduodami klausimai
Kokia yra Capricor Therapeutics akcijos kaina?
Dabartinė Capricor Therapeutics kaina yra 7,59 $.
Koks yra Capricor Therapeutics52 savaičių maksimumas?
52 savaičių maksimumas Capricor Therapeutics yra 40,37 $.
Koks yra Capricor Therapeutics 52 savaičių žemiausias lygis?
52 savaičių žemiausias Capricor Therapeutics kursas yra 2,96 $.
Koks yra Capricor Therapeutics savaitės rezultatas?
Per pastarąją savaitę Capricor Therapeutics kaina pasikeitė −20,36 %.
Koks yra Capricor Therapeutics mėnesio našumas?
Per pastarąjį mėnesį Capricor Therapeutics kaina pasikeitė 14,14 %.
Koks yra Capricor Therapeutics 3 mėnesių rezultatas?
Per pastaruosius tris mėnesius Capricor Therapeutics kaina pasikeitė −4,89 %.
Koks yra Capricor Therapeutics 6 mėnesių rezultatas?
Per pastaruosius šešis mėnesius Capricor Therapeutics kaina pasikeitė −71,81 %.
Koks yra Capricor Therapeuticsmetinis našumas?
Per pastaruosius metus Capricor Therapeutics kaina pasikeitė 31,54 %.